Global Preimplantation Genetic Testing Market By Type (Preimplantation Genetic Screening And Preimplantation Genetic Diagnosis), By Application (Maternity Centers & Fertility Clinics Hospitals, Diagnostic Labs, And Service Providers Research Laboratories & Academic Institutes And ), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2030 (Includes Business Impact of COVID-19)

                                          
Report updated on 11th September, 2021: Global Preimplantation Genetic Testing Market By Type (Preimplantation Genetic Screening And Preimplantation Genetic Diagnosis), By Application (Maternity Centers & Fertility Clinics Hospitals, Diagnostic Labs, And Service Providers Research Laboratories & Academic Institutes And ), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2030 (Includes Business Impact of COVID-19)
Trusted Business Insights has published a comprehensive market research report on, Global Preimplantation Genetic Testing Market by Procedure Type (Preimplantation Genetic Screening and Preimplantation Genetic Diagnosis), By End-User (Maternity Centers & Fertility Clinics, Hospitals & Diagnostic Labs, and Research Laboratories & Academic Institutes), and by Region -Global Forecast to 2030, which offers a holistic view of the global Preimplantation Genetic Testing market through systematic segmentation that covers every aspect of the target market.

The global Preimplantation Genetic Testing market is projected to be US$ 425.7 Mn in 2020 to reach US$ 1458.4 Mn by 2030 at a CAGR of 7.6%.

Preimplantation means embryos are tested before being implanted in the uterus. Other types of genetic tests can be done weeks or months later, post-implantation. Preimplantation genetic testing allows physicians to detect defects that are present in embryos and selectively insert healthy embryos in the uterus, which increases the chances of delivering a genetically healthy baby. Preimplantation genetic testing benefits people to evade any hereditary disorders that prevail in the family, which can be carried into the baby.

There are three types of preimplantation genetic testing (PGT, previously known as PGD or preimplantation genetic diagnosis). These methods include a) PGT-M: Preimplantation genetic testing for monogenic (single-gene) disorders b) PGT-SR: Preimplantation genetic testing for structural rearrangement c) PGT-A: Preimplantation genetic testing for aneuploidy. All require in-vitro fertilization (IVF); biopsy of an embryo, or less commonly polar bodies (I and II) for genetic testing and post which transfer of selected fresh or frozen-thawed embryos into the uterus is done, based on the results of genetic testing.

Preimplantation genetic testing depends on the fact that all of the embryos cells comprise the same genetic information. Preimplantation genetic testing is carried out when a fertilized egg has separated enough times to make an embryo with at least eight cells.

The global preimplantation genetic testing market is expected to observe high growth over the period, due to the increasing number of people seeking IVF treatment for fertility related problems and growing awareness of preimplantation genetic testing for evading birth defects among babies. Increasing acceptance of preimplantation genetic testing in developed and emerging countries is projected to create healthy growth prospects for the market contributors in the global preimplantation genetic testing market.


Global Preimplantation Genetic Testing Market Revenue (US$ Mn), 2021 to 2030


Increasing awareness regarding preimplantation genetic testing among people suffering from genetic disorders is expected to bolster demand for the preimplantation genetic testing market. An increasing number of people suffering from genetic disorders are expected to escalate demand for preimplantation genetic testing procedures.

Also, increasing In-Vitro fertilization treatments across the globe are expected to support the high demand for the preimplantation genetic testing market in the forecast period. Furthermore, high risk of chromosomal abnormalities in the fetus with increasing maternal age is expected to drive preimplantation genetic testing.

However, ethical issues linked with preimplantation genetic testing and strict regulatory policies may affect the growth of preimplantation genetic testing market adversely.


Global Preimplantation Genetic Testing Market by Procedure Type, 2018


On the basis of procedure type, the market is segmented into preimplantation genetic screening and preimplantation genetic diagnosis. Preimplantation genetic screening accounts for the majority share in the global preimplantation genetic testing market.

On the basis of region, the market is segmented into North America, Europe, APAC, South America and MEA. North America accounts majority share in the global preimplantation genetic testing market followed by the market in Europe.

The research report on the global preimplantation genetic testing market includes profiles of some of major companies such as Thermo Fisher Scientific Inc., PerkinElmer, Inc., Abbott Laboratories, Yikon Genomics Co., Ltd., Illumina, Inc., Agilent Technologies, Inc., The Cooper Companies, Inc. (CooperSurgical), Natera, Inc., etc.



Below are the active patents related to Preimplantation Genetic Testing Market.


Patent Number: US20090035762A1

Allele-specific copy number measurement using single nucleotide polymorphism and DNA arrays

Abstract

Methods and systems for allelic detection and allele-specific copy number are provided herein. The described methods use identification of single nucleotide polymorphism using restriction enzymes and CGH analyses. Microarrays comprising probes designed by the described methods are provided. Also included are methods for identifying SNP sites and copy number in samples obtained from patient populations.

Application filed by Date: 2007-07-30

Application Granted Date: 2014-04-01

Current Assignee: Agilent Technologies Inc

Key Market Segments:

By Technology


  
Next Generation Sequencing (NGS)
  
Polymerase Chain Reaction (PCR)
  
Fluorescent In-Situ Hybridization (FISH)
  
Comparative Genomic Hybridization (CGH)
  
Single Nucleotide Polymorphism (SNP

By Procedure Type


  
Preimplantation Genetic Screening
  
Preimplantation Genetic Diagnosis

By Application


  
Aneuploidy
  
Structural Chromosomal Abnormalities
  
Translocations
  
Deletions
  
Duplications
  
Inversions
  
Single Gene Disorders
  
X-linked Disorders
  
HLA Typing
  
Gender Identification

By Products And Services

  
Reagents and Consumables
  
Instruments
  
Software and Services

By End User


  
Maternity Centers & Fertility Clinics
  
Hospitals, Diagnostic Labs, and Service Providers
  
Research Laboratories & Academic Institutes


Key Market Players included in the report:


  
Abbott Laboratories
  
Agilent Technologies Inc. (U.S.)
  
Beijing Genomics Institute (BGI) (China)
  
Bioarray S.L.
  
California Pacific Medical Center
  
Combimatrix Corporation
  
CooperSurgical Inc. (U.S.)
  
F. Hoffmann-La Roche AG
  
Genea Limited
  
Good Start Genetics, Inc.
  
Igenomix SI.
  
Illumina Inc. (U.S.)
  
Invicta Genetics
  
Laboratory Corporation of America Holdings
  
Natera, Inc.
  
Oxford Gene Technology
  
PerkinElmer Inc. (U.S.)
  
Progenesis.
  
Quest Diagnostics Incorporated
  
Reproductive Genetic Innovations, LLC
  
Reproductive Health Science Ltd.
  
Rubicon Genomics (A Subsidiary of Takara Bio Usa Holdings Inc.)
  
Scigene
  
SciGene Corporation.
  
Thermo Fisher Scientific, Inc.
  
Yikon Genomics


Below are the key development related to Preimplantation Genetic Testing Market in 2020 and 2021.


February 2021: Assisted Reproduction Unicorn Basecare Medical to IPO in Hong Kong The planned IPO comes after a very successful and profitable 2020, favorable regulation of industry, and massive growing demand for IVF services in mainland China. Reproductive health firm Suzhou Basecare Medical Co., Ltd will list on the Hong Kong Stock Exchange on February 8 2021. Founded in 2019 in Jiangsu, Basecare has attracted a lot of interest for its self-developed PGT-A test kit that accurately screens each embryo to detect developmental defects and ensure healthy development, allowing more infertile or at-risk couples in China to deliver healthy babies. The market demand for PGT-A products used for limited scientific research purposes increased by 126.8% from the previous year to almost CNY18 million in 2019. Even despite the COVID-19 pandemic, revenue growth climbed by 35.48% in the first 9 months of 2020 to reach CNY15.61 million. Source

July 2020: Strategic Partnership introduces PGT-P to Brazil A new embryo health test that reduces the chance of developing medical conditions such as diabetes, cardiovascular disease, and breast cancer. Would-be parents, in consultation with their doctors and counselors, can now make more informed decisions when choosing which embryo to implant, thanks to an embryo health test known as LifeView™ PGT-P.Strategic Partnership introduces PGT-P to Brazil: Dr. Nathan Treff and Dr. Ciro Martinhago discuss a new embryo health test that reduces the chance of developing medical conditions such as diabetes, cardiovascular disease, and breast cancer. Strategic Partnership introduces PGT-P to Brazil: Dr. Nathan Treff and Dr. Ciro Martinhago discuss a new embryo health test that reduces the chance of developing medical conditions such as diabetes, cardiovascular disease, and breast cancer. Chromosome Medicina Genômica, powered by GeneOne, in partnership with Genomic Prediction and Diagnosticos da America (DASA), is introducing LifeView™ PGT-P to Brazil. By screening for medical conditions, the laboratory can assess risk for common diseases, such as diabetes, common cancers and heart diseases, and mental disorders such as schizophrenia. Embryos can be screened for one condition, several conditions, or all available conditions, and then ordered from lowest to highest risk. The method is validated to reduce disease incidence. Source